CHICAGO, Jan. 20, 2015 /PRNewswire/ -- Positron
Corporation (OTCBB: POSC) is pleased to announce that the United
States Patent and Trademark Office (USPTO) has awarded the
Institute for Nuclear Research (INR) of the Russian Academy of
Sciences a patent (U.S. No. 8,929,503) for the method for producing
strontium-82 (Sr-82) - a precursor to rubidium-82 (Rb-82), the
leading radiopharmaceutical used in Positron Emission Tomography
(PET) myocardial perfusion imaging. It is the second patent for
this technology in North America
included in a license agreement between INR and Positron
Corporation: INR has been awarded a Canadian patent (CA 2719347)
for the same technology in July 2014.
The rights to this patented technology have been granted by INR to
Positron Corporation. Although other licensees, from
France and Russia, can sell Sr-82 produced with the
patented technology, only Positron Corporation has the right to
utilize the technology in North
America.
The Sr-82 production technology was developed by Dr. Воris
Zhuikov, Head of the Laboratory Radioisotope Complex and colleagues
at INR. The developed technology has significant
environmental and economic benefits, as it simplifies the
production process while markedly increasing the yield and quality
of the Sr-82 product derived from rubidium metal.
This improved rubidium metal Sr-82 production process, currently
practiced in Russia as well as by
a French radioisotope production facility, will be applied to
future rubidium metal target processing at Positron's Texas facility. The significant aspect
of this technology is the potential realization of real-time,
continuous Sr-82 production using a rubidium metal target loop on
Positron's proposed 70 MeV cyclotron.
"Positron has been a strong advocate of the advancement,
maturation, and implementation of this patented technology", stated
Jason Kitten, Executive Director of
Radioisotopes for Positron Corporation. "We look forward to working
with INR in building up the strontium-82 production infrastructure
in the US and applying this proven radiostrontium production to our
production capability. "
About Positron: Positron Corporation is a nuclear
medicine healthcare company that specializes in the business of
cardiac PET imaging. Positron is vertically integrating critical
segments of nuclear cardiology to provide an end-to-end solution
for cardiac PET customers. The Company's products and services
include positron emission tomography (PET) molecular imaging
systems, clinical support, radioisotope processing and production
services specifically for cardiac imaging. Positron enables
healthcare providers to more accurately diagnose disease and
improve patient outcomes, while practicing cost effective medicine.
Positron's unique products, market position and approach in
securing the supply chain are substantial advantages, further
accelerating the adoption of cardiac PET and growth of nuclear
cardiology. www.positron.com.
Forward Looking Statements: Statements in this
document contain certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not
guarantees of future performance. These statements may involve
known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of Positron
Corporation to be materially different from future results,
performance or achievements expressed or implied by such
forward-looking statements. Positron assumes no obligation to
publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ
materially from those anticipated in these forward-looking
statements, even if new information becomes available in the
future. Our actual results may differ materially from the
results anticipated in these forward-looking statements due to a
variety of factors, including, without limitation those set forth
as "Risk Factors" in our filings with the Securities and Exchange
Commission.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/institute-for-nuclear-research-of-the-russian-academy-of-sciences-granted-us-patent-for-radiostrontium-production-technology-included-in-licensing-agreement-with-positron-corporation-300022900.html
SOURCE Positron Corporation